← Back to patent-cliff list
Epinephrine inhalation aerosol (Kokua Pharma)
Tier C — Watch / tradeEpinephrine inhalation aerosol (Kokua Pharma)
Kokua Pharma Inc
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：Adrenoceptors
Indications (approved)：CLOVES综合征, Klippel-Trenaunay-Weber综合征, 动静脉畸形, 淋巴管畸形, Allergic reaction
Regional status
US
Phase III
2026-05-13
EU
-
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Epinephrine inhalation aerosol (Kokua Pharma)?
Approved indications include: CLOVES综合征, Klippel-Trenaunay-Weber综合征, 动静脉畸形, 淋巴管畸形, Allergic reaction.
When does the Epinephrine inhalation aerosol (Kokua Pharma) patent expire?
No public expiry year is available for Epinephrine inhalation aerosol (Kokua Pharma) yet; this page updates once verified.
How do I get a quote for Epinephrine inhalation aerosol (Kokua Pharma) intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-29